Filtered By:
Drug: Actos
Education: Study
This page shows you your search results in order of date. This is page number 4.
Order by Relevance | Date
Total 72 results found since Jan 2013.
Antidiabetic agents and cardiovascular outcomes in patients with heart diseases.
This article reviews evidence of benefits and risk of antidiabetic agents in cardiovascular (CV) outcomes, with a focus on medications approved by the FDA since 2008. Peer-reviewed articles were identified from MEDLINE and Current Content database (both 1966 to October 1, 2016) using the search terms insulin, metformin, rosiglitazone, pioglitazone, glyburide, glipizide, glimepiride, acarbose, miglitol, albiglutide, exenatide, liraglutide, lixisenatide, dulaglutide, pramlintide, meglitinide, alogliptin, linagliptin, saxagliptin, sitagliptin, canagliflozin, dapagliflozin, empagliflozin, colesevalam, bromocriptine, mortality,...
Source: Current Medical Research and Opinion - January 19, 2017 Category: Research Tags: Curr Med Res Opin Source Type: research
Dipeptidyl peptidase-4 inhibitors and protection against stroke: A systematic review and meta-analysis.
CONCLUSION: The promising data from experimental studies regarding cardioprotective gliptin-associated effects against stroke were not supported by available data from trials specifically looking at cardiovascular safety.
PMID: 27916514 [PubMed - as supplied by publisher]
Source: Diabetes and Metabolism - November 30, 2016 Category: Endocrinology Authors: Barkas F, Elisaf M, Tsimihodimos V, Milionis H Tags: Diabetes Metab Source Type: research
EMPA-REG and Other Cardiovascular Outcome Trials of Glucose-lowering Agents: Implications for Future Treatment Strategies in Type 2 Diabetes Mellitus.
Abstract
During the last decade, the armamentarium for glucose-lowering drugs has increased enormously by the development of DPP-4 inhibitors, GLP-1 receptor agonists and SGLT2 inhibitors, allowing individualization of antidiabetic therapy for patients with type 2 diabetes (T2DM). Some combinations can now be used without an increased risk for severe hypoglycemia and weight gain. Following a request of the US Food and Drug Administration, many large cardiovascular (CV) outcome studies have been performed in patients with longstanding disease and established CV disease. In the majority of CV outcome studies, CV ris...
Source: Clinical Therapeutics - May 18, 2016 Category: Drugs & Pharmacology Authors: Schernthaner G, Schernthaner-Reiter MH, Schernthaner GH Tags: Clin Ther Source Type: research
Diabetes drug pioglitazone could get personal: Neither panacea, nor peril
When I was in training, one of my beloved mentors declared, “I never use a drug until it’s been on the market for 20 years.” I was young enough then that I couldn’t fathom being a doctor for 20 years, let alone waiting two decades to use a new drug. As my career has progressed, I’ve seen many new drugs released to the market. Some of them are truly miraculous, bringing people longer, healthier, and more productive lives. Many of them have not withstood the test of time. More than a few have even been taken off the market. Even though the Food and Drug Administration diligently reviews each new medicine before it...
Source: New Harvard Health Information - May 5, 2016 Category: Consumer Health News Authors: Lori Wiviott Tishler, MD, MPH Tags: Diabetes Drugs and Supplements pioglitazone thiazolidinediones Source Type: news
Revitalization of pioglitazone: the optimum agent to be combined with a sodium‐glucose co‐transporter‐2 inhibitor
The recently completed EMPA‐REG study showed that empagliflozin significantly decreased the major adverse cardiac events (MACE) endpoint, which comprised cardiovascular death, non‐fatal myocardial infarction (MI) and stroke, in patients with high‐risk type 2 diabetes (T2DM), primarily through a reduction in cardiovascular death, without a significant decrease in either MI or stroke. In the PROactive study, pioglitazone decreased the MACE endpoint by a similar degree to that observed in the EMPA‐REG study, through a marked reduction in both recurrent MI and stroke and a modest reduction in cardiovascular death. Thes...
Source: Diabetes, Obesity and Metabolism - April 5, 2016 Category: Endocrinology Authors: R. A. DeFronzo, R. Chilton, L. Norton, G. Clarke, R. E. J. Ryder, M. Abdul‐Ghani Tags: PERSPECTIVE Source Type: research
New front opens in battle against stroke
Medical scientists have vetted a potentially powerful new tool for helping prevent stroke and heart attack. In a study, researchers show that pioglitazone, a member of the insulin-sensitizing class of medications called thiazolidinediones, reduced the risk of stroke or heart attack by almost a quarter in patients who had previously suffered a stroke or mini-stroke.
Source: ScienceDaily Headlines - February 25, 2016 Category: Science Source Type: news
Revitalization of Pioglitazone: The Optimal Agent to be Combined with an SGLT2 Inhibitor
ABSTRACT
The recently completed EMPA‐REG study demonstrated that empagliflozin significantly decreased the MACE endpoint (cardiovascular death, nonfatal MI, stroke) in high risk type 2 diabetic patients, primarily due to a reduction in cardiovascular death, without a significant decrease in either myocardial infarction or stroke. In PROactive, pioglitazone decreased the MACE endpoint by a similar degree to that in EMPA‐REG, due to a marked reduction in both recurrent myocardial infarction and stroke and a modest reduction in cardiovascular death. These observations suggest that pioglitazone might be an ideal agent to c...
Source: Diabetes, Obesity and Metabolism - February 25, 2016 Category: Endocrinology Authors: Ralph A. DeFronzo, Robert Chilton, Luke Norton, Geoffrey Clarke, Robert E.J. Ryder, Muhammad Abdul‐Ghani Tags: ORIGINAL ARTICLE Source Type: research
Pioglitazone for Secondary Prevention in Vascular Disease? (FREE)
By Joe Elia
Edited by Jaye Elizabeth Hefner, MD
Pioglitazone, which lowers insulin resistance, may help in the secondary prevention of vascular events, suggests a study presented at the International Stroke Conference and published in the New England …
Source: Physician's First Watch current issue - February 18, 2016 Category: Primary Care Source Type: news
Diabetes Drug May Help Prevent Second Stroke: Study
Actos reduced risk by 24 percent in people with insulin resistance, research showed
Source: WebMD Health - February 17, 2016 Category: Consumer Health News Source Type: news
Diabetes drug may prevent recurring strokes
This study was supported by the NIH's National Institute of Neurological Disorders and Stroke.
Source: EurekAlert! - Medicine and Health - February 17, 2016 Category: Global & Universal Source Type: news
Ten‐year observational follow‐up of PROactive: a randomized cardiovascular outcomes trial evaluating pioglitazone in type 2 diabetes
ConclusionsThe trends of macrovascular benefits of pioglitazone compared with placebo during PROactive did not persist in the absence of continued pioglitazone during this 10‐year follow‐up. Trends of decreased bladder cancer and increased prostate cancer were observed in the pioglitazone group during follow‐up; however, these imbalances should be interpreted with caution because of the limitations of the observational study design.
Source: Diabetes, Obesity and Metabolism - January 8, 2016 Category: Endocrinology Authors: E. Erdmann, S. Harding, H. Lam, A. Perez Tags: ORIGINAL ARTICLE Source Type: research
10‐Year Observational Follow‐Up of PROactive: a randomized cardiovascular outcomes trial evaluating pioglitazone in type 2 diabetes
ConclusionsThe trends of macrovascular benefits of pioglitazone compared with placebo during PROactive did not persist in the absence of continued pioglitazone during this 10‐year follow‐up. Trends of decreased bladder cancer and increased prostate cancer were observed in the pioglitazone group during follow‐up; however, these imbalances should be interpreted with caution due to limitations of the observational study design.
Source: Diabetes, Obesity and Metabolism - November 23, 2015 Category: Endocrinology Authors: Erland Erdmann, Sarah Harding, Hung Lam, Alfonso Perez Tags: ORIGINAL ARTICLE Source Type: research
Peroxisome proliferator-activated receptor gamma agonists for preventing recurrent stroke and other vascular events in patients with stroke or transient ischaemic attack.
CONCLUSIONS: PPAR-γ agonists appear to reduce recurrent stroke and total events of cardiovascular death, non-fatal myocardial infarction or non-fatal stroke, and improve insulin sensitivity and the stabilisation of carotid plaques. There is evidence of limited quality that they are well tolerated. However, the conclusions should be interpreted with caution considering the small number and the quality of the included studies. In future, well-designed, double-blind RCTs with large samples are required to assess the efficacy and safety of PPAR-γ agonists in the secondary prevention of stroke and related vascular events in p...
Source: Cochrane Database of Systematic Reviews - October 29, 2015 Category: Journals (General) Authors: Liu J, Wang LN Tags: Cochrane Database Syst Rev Source Type: research
